FI107158B - Menetelmä kondensoitujen indolikarboksylaatti- ja indolikarboksiamidijohdannaisten valmistamiseksi - Google Patents
Menetelmä kondensoitujen indolikarboksylaatti- ja indolikarboksiamidijohdannaisten valmistamiseksi Download PDFInfo
- Publication number
- FI107158B FI107158B FI944204A FI944204A FI107158B FI 107158 B FI107158 B FI 107158B FI 944204 A FI944204 A FI 944204A FI 944204 A FI944204 A FI 944204A FI 107158 B FI107158 B FI 107158B
- Authority
- FI
- Finland
- Prior art keywords
- indole
- methyl
- piperidyl
- carboxylate
- nmr
- Prior art date
Links
- VFHUJFBEFDVZPJ-UHFFFAOYSA-N 1h-indole-2-carboxamide Chemical class C1=CC=C2NC(C(=O)N)=CC2=C1 VFHUJFBEFDVZPJ-UHFFFAOYSA-N 0.000 title claims description 3
- HCUARRIEZVDMPT-UHFFFAOYSA-M 1h-indole-2-carboxylate Chemical compound C1=CC=C2NC(C(=O)[O-])=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-M 0.000 title claims description 3
- 238000004519 manufacturing process Methods 0.000 title description 2
- 238000000034 method Methods 0.000 claims description 74
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 49
- -1 polymethylene chain Polymers 0.000 claims description 38
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 229910052736 halogen Chemical group 0.000 claims description 3
- 150000002367 halogens Chemical group 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims 2
- CMKDJMDGRSJZIS-UHFFFAOYSA-N 2,3-dihydro-1h-indene-1-carbaldehyde Chemical compound C1=CC=C2C(C=O)CCC2=C1 CMKDJMDGRSJZIS-UHFFFAOYSA-N 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 118
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 108
- 150000001875 compounds Chemical class 0.000 description 105
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 90
- 239000007787 solid Substances 0.000 description 88
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 87
- 239000000243 solution Substances 0.000 description 83
- 238000005481 NMR spectroscopy Methods 0.000 description 78
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 62
- 239000011734 sodium Substances 0.000 description 52
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 47
- 239000000203 mixture Substances 0.000 description 44
- 239000003921 oil Substances 0.000 description 41
- 235000019198 oils Nutrition 0.000 description 41
- 239000000741 silica gel Substances 0.000 description 41
- 229910002027 silica gel Inorganic materials 0.000 description 41
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 40
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 40
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 30
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 29
- 239000000284 extract Substances 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 229910000027 potassium carbonate Inorganic materials 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000012230 colorless oil Substances 0.000 description 18
- 239000000543 intermediate Substances 0.000 description 18
- 150000003891 oxalate salts Chemical class 0.000 description 18
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 17
- 229910052708 sodium Inorganic materials 0.000 description 17
- 239000012043 crude product Substances 0.000 description 16
- 235000019441 ethanol Nutrition 0.000 description 16
- 239000012458 free base Substances 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 16
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 15
- 238000010992 reflux Methods 0.000 description 15
- 239000000725 suspension Substances 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 238000004587 chromatography analysis Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 10
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- QXAUTQFAWKKNLM-UHFFFAOYSA-N methyl indole-3-carboxylate Natural products C1=CC=C2C(C(=O)OC)=CNC2=C1 QXAUTQFAWKKNLM-UHFFFAOYSA-N 0.000 description 9
- 239000003208 petroleum Substances 0.000 description 9
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- UKLGEVKLGKJFQI-UHFFFAOYSA-N CCCCN(CC1)CCC1OC(C1=C2OC(C)CCN2C2=C1C=CC=C2)=O Chemical compound CCCCN(CC1)CCC1OC(C1=C2OC(C)CCN2C2=C1C=CC=C2)=O UKLGEVKLGKJFQI-UHFFFAOYSA-N 0.000 description 8
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
- 235000019502 Orange oil Nutrition 0.000 description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 8
- 239000010502 orange oil Substances 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- 239000003523 serotonin 4 antagonist Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 208000002551 irritable bowel syndrome Diseases 0.000 description 7
- LSGKMZLPZFPAIN-UHFFFAOYSA-N 1h-indole-3-carboxamide Chemical compound C1=CC=C2C(C(=O)N)=CNC2=C1 LSGKMZLPZFPAIN-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 208000019695 Migraine disease Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- KMAKOBLIOCQGJP-UHFFFAOYSA-N indole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CNC2=C1 KMAKOBLIOCQGJP-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 206010027599 migraine Diseases 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 6
- MKGIQRNAGSSHRV-UHFFFAOYSA-N 1,1-dimethyl-4-phenylpiperazin-1-ium Chemical compound C1C[N+](C)(C)CCN1C1=CC=CC=C1 MKGIQRNAGSSHRV-UHFFFAOYSA-N 0.000 description 5
- 108091005482 5-HT4 receptors Proteins 0.000 description 5
- 206010003130 Arrhythmia supraventricular Diseases 0.000 description 5
- KBSNNUAQCDKOLL-UHFFFAOYSA-N [1,3]thiazolo[3,2-a]indole-4-carboxylic acid Chemical compound C1=CC=C2N(C=CS3)C3=C(C(=O)O)C2=C1 KBSNNUAQCDKOLL-UHFFFAOYSA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 5
- KNUKUWNSGVICSX-UHFFFAOYSA-N (1-benzylpiperidin-4-yl)methanamine Chemical compound C1CC(CN)CCN1CC1=CC=CC=C1 KNUKUWNSGVICSX-UHFFFAOYSA-N 0.000 description 4
- FLQPYEOKVZYXRL-UHFFFAOYSA-N (1-benzylpiperidin-4-yl)methanol Chemical compound C1CC(CO)CCN1CC1=CC=CC=C1 FLQPYEOKVZYXRL-UHFFFAOYSA-N 0.000 description 4
- IIJFYTVJRDKVCI-UHFFFAOYSA-N 1h-indole-3-carbonyl chloride Chemical compound C1=CC=C2C(C(=O)Cl)=CNC2=C1 IIJFYTVJRDKVCI-UHFFFAOYSA-N 0.000 description 4
- RIPCDSAZUUSSJZ-UHFFFAOYSA-N 2,3-dihydro-1h-pyrrolo[1,2-a]indole-4-carboxylic acid Chemical compound C12=CC=CC=C2C(C(=O)O)=C2N1CCC2 RIPCDSAZUUSSJZ-UHFFFAOYSA-N 0.000 description 4
- WJOIMBFFFBIKMN-UHFFFAOYSA-N 6,7-dihydropyrido[1,2-a]indole-10-carboxylic acid Chemical compound C12=CC=CC=C2C(C(=O)O)=C2N1CCC=C2 WJOIMBFFFBIKMN-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 239000005909 Kieselgur Substances 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- UELJXCRPLCATAK-UHFFFAOYSA-N ethyl 2-(2-aminophenyl)acetate Chemical compound CCOC(=O)CC1=CC=CC=C1N UELJXCRPLCATAK-UHFFFAOYSA-N 0.000 description 4
- FXCLGAGFIKPOQS-UHFFFAOYSA-N n-[(1-butylpiperidin-4-yl)methyl]-1h-indole-3-carboxamide Chemical compound C1CN(CCCC)CCC1CNC(=O)C1=CNC2=CC=CC=C12 FXCLGAGFIKPOQS-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- RPJYZKGYSLMAOJ-UHFFFAOYSA-N pyrido[1,2-a]indole-10-carboxylic acid Chemical compound C1=CC=CC2=C(C(=O)O)C3=CC=CC=C3N21 RPJYZKGYSLMAOJ-UHFFFAOYSA-N 0.000 description 4
- 229940044551 receptor antagonist Drugs 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- 230000003997 social interaction Effects 0.000 description 4
- WZHMOTQORPSBLK-UHFFFAOYSA-N (1-benzylpiperidin-4-yl)methyl 3,4-dihydro-2h-[1,3]oxazino[3,2-a]indole-10-carboxylate Chemical compound C=12OCCCN2C2=CC=CC=C2C=1C(=O)OCC(CC1)CCN1CC1=CC=CC=C1 WZHMOTQORPSBLK-UHFFFAOYSA-N 0.000 description 3
- BTQRLOXTXUREID-UHFFFAOYSA-N 2-piperidin-1-ylethyl 3,4-dihydro-2h-[1,3]oxazino[3,2-a]indole-10-carboxylate Chemical compound C=12OCCCN2C2=CC=CC=C2C=1C(=O)OCCN1CCCCC1 BTQRLOXTXUREID-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010003658 Atrial Fibrillation Diseases 0.000 description 3
- SFOQXARZHVEZAH-UHFFFAOYSA-N CC1=CN2C(=C(C=3C=CC=CC23)C(=O)OC2CCN(CC2)CCCC)S1 Chemical compound CC1=CN2C(=C(C=3C=CC=CC23)C(=O)OC2CCN(CC2)CCCC)S1 SFOQXARZHVEZAH-UHFFFAOYSA-N 0.000 description 3
- RDVJGXLUNSTXTI-UHFFFAOYSA-N CC1N(C=2N(C=3C=CC=CC3C2C(=O)OC2CCN(CC2)CCCC)CC1)C Chemical compound CC1N(C=2N(C=3C=CC=CC3C2C(=O)OC2CCN(CC2)CCCC)CC1)C RDVJGXLUNSTXTI-UHFFFAOYSA-N 0.000 description 3
- BCNRIJJCXDNXGF-UHFFFAOYSA-N CCCCN(CC1)CCC1OC(C1=C(CCCC2)N2C2=CC=CC(C)=C12)=O Chemical compound CCCCN(CC1)CCC1OC(C1=C(CCCC2)N2C2=CC=CC(C)=C12)=O BCNRIJJCXDNXGF-UHFFFAOYSA-N 0.000 description 3
- KKURMERFGLKHAC-UHFFFAOYSA-N CCCCN(CC1)CCC1OC(C1=C2N(C)CCCN2C2=C1C=CC=C2)=O Chemical compound CCCCN(CC1)CCC1OC(C1=C2N(C)CCCN2C2=C1C=CC=C2)=O KKURMERFGLKHAC-UHFFFAOYSA-N 0.000 description 3
- JURLTGZYTFYJKR-UHFFFAOYSA-N CCCCN(CC1)CCC1OC(C1=C2N=C(C)C(C)=C(C)N2C2=C1C=CC=C2)=O Chemical compound CCCCN(CC1)CCC1OC(C1=C2N=C(C)C(C)=C(C)N2C2=C1C=CC=C2)=O JURLTGZYTFYJKR-UHFFFAOYSA-N 0.000 description 3
- RYUHYKHVQOXXEN-UHFFFAOYSA-N CCCCN(CC1)CCC1OC(C1=C2OC(C)CN2C2=C1C=CC=C2)=O Chemical compound CCCCN(CC1)CCC1OC(C1=C2OC(C)CN2C2=C1C=CC=C2)=O RYUHYKHVQOXXEN-UHFFFAOYSA-N 0.000 description 3
- XQZQRDBNRSMSPB-UHFFFAOYSA-N CCCCN(CC1)CCC1OC(C1=C2SC(C)=C(C)N2C2=C1C=CC=C2)=O Chemical compound CCCCN(CC1)CCC1OC(C1=C2SC(C)=C(C)N2C2=C1C=CC=C2)=O XQZQRDBNRSMSPB-UHFFFAOYSA-N 0.000 description 3
- VWFSHOSAENMPRJ-UHFFFAOYSA-N COC(=O)C1=C2CCCCCN2C3=CC=CC=C31 Chemical compound COC(=O)C1=C2CCCCCN2C3=CC=CC=C31 VWFSHOSAENMPRJ-UHFFFAOYSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- KKQQFVYJPXLAMT-UHFFFAOYSA-N N-[(1-hexylpiperidin-4-yl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide Chemical compound C1CN(CCCCCC)CCC1CNC(=O)C(C1=CC=CC=C11)=C2N1CCCO2 KKQQFVYJPXLAMT-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 150000004678 hydrides Chemical class 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 150000002475 indoles Chemical class 0.000 description 3
- STWVKDYCLCUPSA-UHFFFAOYSA-N methyl 1,2,3,4-tetrahydropyrimido[1,2-a]indole-10-carboxylate Chemical compound C12=CC=CC=C2C(C(=O)OC)=C2N1CCCN2 STWVKDYCLCUPSA-UHFFFAOYSA-N 0.000 description 3
- YODYXZOJWGXFSQ-UHFFFAOYSA-N methyl 2-chloro-1h-indole-3-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)=C(Cl)NC2=C1 YODYXZOJWGXFSQ-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- VHHOSEVGENQMGE-UHFFFAOYSA-N n-[(1-benzylpiperidin-4-yl)methyl]-3,4-dihydro-2h-[1,3]oxazino[3,2-a]indole-10-carboxamide Chemical compound C=12OCCCN2C2=CC=CC=C2C=1C(=O)NCC(CC1)CCN1CC1=CC=CC=C1 VHHOSEVGENQMGE-UHFFFAOYSA-N 0.000 description 3
- PGHPCUKCHSSIIE-UHFFFAOYSA-N n-[[1-(cyclohexylmethyl)piperidin-4-yl]methyl]-3,4-dihydro-2h-[1,3]oxazino[3,2-a]indole-10-carboxamide Chemical compound C=12OCCCN2C2=CC=CC=C2C=1C(=O)NCC(CC1)CCN1CC1CCCCC1 PGHPCUKCHSSIIE-UHFFFAOYSA-N 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- KVCSJPATKXABRQ-UHFFFAOYSA-N piboserod Chemical compound C1CN(CCCC)CCC1CNC(=O)C(C1=CC=CC=C11)=C2N1CCCO2 KVCSJPATKXABRQ-UHFFFAOYSA-N 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 235000009518 sodium iodide Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- ZBPFTTMINCTOHB-UHFFFAOYSA-N (1-butylpiperidin-4-yl) 1-methylindole-3-carboxylate Chemical compound CN1C=C(C2=CC=CC=C12)C(=O)OC1CCN(CC1)CCCC ZBPFTTMINCTOHB-UHFFFAOYSA-N 0.000 description 2
- WBJOIIUQZHTVOG-UHFFFAOYSA-N (1-butylpiperidin-4-yl)methanol Chemical compound CCCCN1CCC(CO)CC1 WBJOIIUQZHTVOG-UHFFFAOYSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- MPEUCZGCMAPFTF-UHFFFAOYSA-N 1,2-dihydro-[1,3]thiazolo[3,2-a]indole Chemical compound C1=CC=C2N3CCSC3=CC2=C1 MPEUCZGCMAPFTF-UHFFFAOYSA-N 0.000 description 2
- HBQIITMSFPSBAF-UHFFFAOYSA-N 1,2-dihydro-[1,3]thiazolo[3,2-a]indole-4-carboxylic acid Chemical compound C12=CC=CC=C2C(C(=O)O)=C2N1CCS2 HBQIITMSFPSBAF-UHFFFAOYSA-N 0.000 description 2
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 2
- GPXQCDMLWATWCA-UHFFFAOYSA-N 1-methyl-[1,3]thiazolo[3,2-a]indole-4-carboxylic acid Chemical compound C1=CC=C2N3C(C)=CSC3=C(C(O)=O)C2=C1 GPXQCDMLWATWCA-UHFFFAOYSA-N 0.000 description 2
- 229940044613 1-propanol Drugs 0.000 description 2
- YGKPIROTKVQCCU-UHFFFAOYSA-N 1H-indole-3-carboxylic acid 2-(1-piperidinyl)ethyl ester Chemical compound C=1NC2=CC=CC=C2C=1C(=O)OCCN1CCCCC1 YGKPIROTKVQCCU-UHFFFAOYSA-N 0.000 description 2
- LNDMOIIJTXMMMB-UHFFFAOYSA-N 2,2,2-trifluoro-1-(1-methyl-[1,3]thiazolo[3,2-a]indol-4-yl)ethanone Chemical compound C1=CC=C2N3C(C)=CSC3=C(C(=O)C(F)(F)F)C2=C1 LNDMOIIJTXMMMB-UHFFFAOYSA-N 0.000 description 2
- PASJVWQAHRQSLY-UHFFFAOYSA-N 2,2,2-trifluoro-1-([1,3]thiazolo[3,2-a]indol-4-yl)ethanone Chemical compound C1=CC=C2N(C=CS3)C3=C(C(=O)C(F)(F)F)C2=C1 PASJVWQAHRQSLY-UHFFFAOYSA-N 0.000 description 2
- OYJGEOAXBALSMM-UHFFFAOYSA-N 2,3-dihydro-1,3-thiazole Chemical compound C1NC=CS1 OYJGEOAXBALSMM-UHFFFAOYSA-N 0.000 description 2
- XQSBNCPFMSWWID-UHFFFAOYSA-N 2-(2,2-diethoxyethylsulfanyl)-1h-indole Chemical compound C1=CC=C2NC(SCC(OCC)OCC)=CC2=C1 XQSBNCPFMSWWID-UHFFFAOYSA-N 0.000 description 2
- BVRPJWUGPLNQRX-UHFFFAOYSA-N 2-amino-1h-indole-3-carboxylic acid Chemical compound C1=CC=C2C(C(O)=O)=C(N)NC2=C1 BVRPJWUGPLNQRX-UHFFFAOYSA-N 0.000 description 2
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 2
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 description 2
- HXHGULXINZUGJX-UHFFFAOYSA-N 4-chlorobutanol Chemical compound OCCCCCl HXHGULXINZUGJX-UHFFFAOYSA-N 0.000 description 2
- 229940113081 5 Hydroxytryptamine 3 receptor antagonist Drugs 0.000 description 2
- JRWWQVUFPAVLGO-UHFFFAOYSA-N 6,7,8,9-tetrahydropyrido[1,2-a]indole-10-carboxylic acid Chemical compound C12=CC=CC=C2C(C(=O)O)=C2N1CCCC2 JRWWQVUFPAVLGO-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- FKGJNXNMDIPXSN-UHFFFAOYSA-N CC1=C2C(=C3N(C2=CC=C1)C=CC=C3)C(=O)OC3CCN(CC3)CCCC Chemical compound CC1=C2C(=C3N(C2=CC=C1)C=CC=C3)C(=O)OC3CCN(CC3)CCCC FKGJNXNMDIPXSN-UHFFFAOYSA-N 0.000 description 2
- WACSBOVYRCUHIC-UHFFFAOYSA-N CC1=C2C(=C3N(C2=CC=C1)CCC=C3)C(=O)OC3CCN(CC3)CCCC Chemical compound CC1=C2C(=C3N(C2=CC=C1)CCC=C3)C(=O)OC3CCN(CC3)CCCC WACSBOVYRCUHIC-UHFFFAOYSA-N 0.000 description 2
- HFTKRARWLLLCNP-UHFFFAOYSA-N CC1=CC(=NC2=C(C3=CC=CC=C3N12)C(=O)O)C Chemical compound CC1=CC(=NC2=C(C3=CC=CC=C3N12)C(=O)O)C HFTKRARWLLLCNP-UHFFFAOYSA-N 0.000 description 2
- FCKSEYLYFNSOJS-UHFFFAOYSA-N CCCCN(CC1)CCC1OC(C1=C2N=C(C)C=CN2C2=C1C=CC=C2)=O Chemical compound CCCCN(CC1)CCC1OC(C1=C2N=C(C)C=CN2C2=C1C=CC=C2)=O FCKSEYLYFNSOJS-UHFFFAOYSA-N 0.000 description 2
- FOQAPCCNOQASML-UHFFFAOYSA-N CCCCN(CC1)CCC1OC(C1=C2SC(C)CN2C2=C1C=CC=C2)=O Chemical compound CCCCN(CC1)CCC1OC(C1=C2SC(C)CN2C2=C1C=CC=C2)=O FOQAPCCNOQASML-UHFFFAOYSA-N 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- FDFXXWIRTGBXAR-UHFFFAOYSA-N N-[(1-butylpiperidin-4-yl)methyl]-2,3-dihydro-1H-pyrrolo[1,2-a]indole-4-carboxamide Chemical compound C1CN(CCCC)CCC1CNC(=O)C(C1=CC=CC=C11)=C2N1CCC2 FDFXXWIRTGBXAR-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- NKEGHPOGONHAJP-UHFFFAOYSA-N [1,3]thiazolo[3,2-a]indole Chemical compound C1=CC=C2N3C=CSC3=CC2=C1 NKEGHPOGONHAJP-UHFFFAOYSA-N 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001746 atrial effect Effects 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000009194 climbing Effects 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229940095074 cyclic amp Drugs 0.000 description 2
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 239000008157 edible vegetable oil Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- JDMCKRPUEOBJHJ-UHFFFAOYSA-N ethyl 2,3-dihydro-1h-pyrrolo[1,2-a]indole-4-carboxylate Chemical compound C12=CC=CC=C2C(C(=O)OCC)=C2N1CCC2 JDMCKRPUEOBJHJ-UHFFFAOYSA-N 0.000 description 2
- OEKWLWGLAKDLIY-UHFFFAOYSA-N ethyl 2-[2-(5-chloropentanoylamino)phenyl]acetate Chemical compound CCOC(=O)CC1=CC=CC=C1NC(=O)CCCCCl OEKWLWGLAKDLIY-UHFFFAOYSA-N 0.000 description 2
- NWSYAJOTNKEBNL-UHFFFAOYSA-N ethyl 7,8,9,10-tetrahydro-6h-azepino[1,2-a]indole-11-carboxylate Chemical compound C1CCCCN2C3=CC=CC=C3C(C(=O)OCC)=C21 NWSYAJOTNKEBNL-UHFFFAOYSA-N 0.000 description 2
- RUJPPJYDHHAEEK-UHFFFAOYSA-N ethyl piperidine-4-carboxylate Chemical compound CCOC(=O)C1CCNCC1 RUJPPJYDHHAEEK-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000010243 gut motility Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N iodoform Chemical compound IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- IMKKVSYOKTZVBO-UHFFFAOYSA-N methyl pyrimido[1,2-a]indole-10-carboxylate Chemical compound C1=CC=NC2=C(C(=O)OC)C3=CC=CC=C3N21 IMKKVSYOKTZVBO-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- BXVCFLARGCBLEP-UHFFFAOYSA-N n-(2-bromoethyl)methanesulfonamide Chemical compound CS(=O)(=O)NCCBr BXVCFLARGCBLEP-UHFFFAOYSA-N 0.000 description 2
- JDCHIBIXWGFOBR-UHFFFAOYSA-N n-[(1-butylpiperidin-4-yl)methyl]-2-chloro-1h-indole-3-carboxamide Chemical compound C1CN(CCCC)CCC1CNC(=O)C1=C(Cl)NC2=CC=CC=C12 JDCHIBIXWGFOBR-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000004533 oil dispersion Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- XUGQMJOUKXSKPZ-UHFFFAOYSA-N pyrimido[1,2-a]indole-10-carboxylic acid Chemical compound C1=CC=NC2=C(C(=O)O)C3=CC=CC=C3N21 XUGQMJOUKXSKPZ-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 229960002317 succinimide Drugs 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- HXZJJPILPZILKZ-UHFFFAOYSA-N (1-benzylpiperidin-4-yl)methyl 1h-indole-3-carboxylate Chemical compound C=1NC2=CC=CC=C2C=1C(=O)OCC(CC1)CCN1CC1=CC=CC=C1 HXZJJPILPZILKZ-UHFFFAOYSA-N 0.000 description 1
- KOMXBXCRESWSNG-UHFFFAOYSA-N (1-butylpiperidin-4-yl) 2-methyl-1H-indole-3-carboxylate Chemical compound CC=1NC2=CC=CC=C2C=1C(=O)OC1CCN(CC1)CCCC KOMXBXCRESWSNG-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 1
- XHTYQFMRBQUCPX-UHFFFAOYSA-N 1,1,3,3-tetramethoxypropane Chemical compound COC(OC)CC(OC)OC XHTYQFMRBQUCPX-UHFFFAOYSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- MGCWCUBVCXHCBZ-UHFFFAOYSA-N 1-(1,2-dihydro-[1,3]thiazolo[3,2-a]indol-4-yl)-2,2,2-trifluoroethanone Chemical compound C12=CC=CC=C2C(C(=O)C(F)(F)F)=C2N1CCS2 MGCWCUBVCXHCBZ-UHFFFAOYSA-N 0.000 description 1
- MNDIARAMWBIKFW-UHFFFAOYSA-N 1-bromohexane Chemical compound CCCCCCBr MNDIARAMWBIKFW-UHFFFAOYSA-N 0.000 description 1
- PJWZTMATHPXZCW-UHFFFAOYSA-N 1-butyl-n-methylpiperidin-4-amine Chemical compound CCCCN1CCC(NC)CC1 PJWZTMATHPXZCW-UHFFFAOYSA-N 0.000 description 1
- ZAWGCCCUSVQMFN-UHFFFAOYSA-N 1-methyl-[1,3]thiazolo[3,2-a]indole Chemical compound C1=CC=C2N3C(C)=CSC3=CC2=C1 ZAWGCCCUSVQMFN-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- SHRJPIBSGVMGNL-UHFFFAOYSA-N 2-(3-bromopropoxy)-1h-indole Chemical compound C1=CC=C2NC(OCCCBr)=CC2=C1 SHRJPIBSGVMGNL-UHFFFAOYSA-N 0.000 description 1
- KZTWONRVIPPDKH-UHFFFAOYSA-N 2-(piperidin-1-yl)ethanol Chemical compound OCCN1CCCCC1 KZTWONRVIPPDKH-UHFFFAOYSA-N 0.000 description 1
- LILXDMFJXYAKMK-UHFFFAOYSA-N 2-bromo-1,1-diethoxyethane Chemical compound CCOC(CBr)OCC LILXDMFJXYAKMK-UHFFFAOYSA-N 0.000 description 1
- WJAXXWSZNSFVNG-UHFFFAOYSA-N 2-bromoethanamine;hydron;bromide Chemical compound [Br-].[NH3+]CCBr WJAXXWSZNSFVNG-UHFFFAOYSA-N 0.000 description 1
- SXIIAHIAZAMFPW-UHFFFAOYSA-N 2-chloro-1h-indole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(Cl)NC2=C1 SXIIAHIAZAMFPW-UHFFFAOYSA-N 0.000 description 1
- ZMEZACDEDHDTCJ-UHFFFAOYSA-N 2h-[1,3]oxazino[3,2-a]indole-10-carboxamide Chemical compound C12=CC=CC=C2C(C(=O)N)=C2N1C=CCO2 ZMEZACDEDHDTCJ-UHFFFAOYSA-N 0.000 description 1
- ZTGQZSKPSJUEBU-UHFFFAOYSA-N 3-bromopropan-1-amine Chemical compound NCCCBr ZTGQZSKPSJUEBU-UHFFFAOYSA-N 0.000 description 1
- RMVOXEVCGLDIKU-UHFFFAOYSA-N 3-chloro-1-n,1-n'-dimethylpropane-1,1-diamine Chemical compound CNC(NC)CCCl RMVOXEVCGLDIKU-UHFFFAOYSA-N 0.000 description 1
- BZFKSWOGZQMOMO-UHFFFAOYSA-N 3-chloropropan-1-amine Chemical compound NCCCCl BZFKSWOGZQMOMO-UHFFFAOYSA-N 0.000 description 1
- TZCFWOHAWRIQGF-UHFFFAOYSA-N 3-chloropropane-1-thiol Chemical compound SCCCCl TZCFWOHAWRIQGF-UHFFFAOYSA-N 0.000 description 1
- GZSKEXSLDPEFPT-HZMBPMFUSA-N 4-amino-n-[(4s,5s)-1-azabicyclo[3.3.1]nonan-4-yl]-5-chloro-2-methoxybenzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)N[C@@H]1[C@H](C2)CCCN2CC1 GZSKEXSLDPEFPT-HZMBPMFUSA-N 0.000 description 1
- 229940127239 5 Hydroxytryptamine receptor antagonist Drugs 0.000 description 1
- 108091005478 5-HT1 receptors Proteins 0.000 description 1
- 102000035038 5-HT1 receptors Human genes 0.000 description 1
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
- 108091005479 5-HT2 receptors Proteins 0.000 description 1
- 102000035037 5-HT3 receptors Human genes 0.000 description 1
- 108091005477 5-HT3 receptors Proteins 0.000 description 1
- SVNNWKWHLOJLOK-UHFFFAOYSA-N 5-chloropentanoyl chloride Chemical compound ClCCCCC(Cl)=O SVNNWKWHLOJLOK-UHFFFAOYSA-N 0.000 description 1
- SDZBAXLIHRBNOV-UHFFFAOYSA-N 5-fluoro-1h-indole-3-carboxylic acid Chemical compound C1=C(F)C=C2C(C(=O)O)=CNC2=C1 SDZBAXLIHRBNOV-UHFFFAOYSA-N 0.000 description 1
- JJIUISYYTFDATN-UHFFFAOYSA-N 5-fluoro-2-methyl-1h-indole Chemical compound FC1=CC=C2NC(C)=CC2=C1 JJIUISYYTFDATN-UHFFFAOYSA-N 0.000 description 1
- HBPVGJGBRWIVSX-UHFFFAOYSA-N 6-bromohexanoyl chloride Chemical compound ClC(=O)CCCCCBr HBPVGJGBRWIVSX-UHFFFAOYSA-N 0.000 description 1
- AFLHXJFLNQOYDV-UHFFFAOYSA-N 7,8,9,10-tetrahydro-6h-azepino[1,2-a]indole-11-carboxylic acid Chemical compound C1CCCCN2C3=CC=CC=C3C(C(=O)O)=C21 AFLHXJFLNQOYDV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- DFWAJGVZGNWTDL-UHFFFAOYSA-N C(CCC)N1CCC(CC1)CN1C=CC2=CC=CC=C12 Chemical compound C(CCC)N1CCC(CC1)CN1C=CC2=CC=CC=C12 DFWAJGVZGNWTDL-UHFFFAOYSA-N 0.000 description 1
- MZZNZGJZCBBXER-UHFFFAOYSA-N CC1=C2C(=C3N(C2=CC=C1)C=CC=C3)C(=O)O Chemical compound CC1=C2C(=C3N(C2=CC=C1)C=CC=C3)C(=O)O MZZNZGJZCBBXER-UHFFFAOYSA-N 0.000 description 1
- VIKWXRMCVRWJES-UHFFFAOYSA-N CC1CCN2C1=C(C=1C=CC=CC21)C(=O)OC2CCN(CC2)CCCC Chemical compound CC1CCN2C1=C(C=1C=CC=CC21)C(=O)OC2CCN(CC2)CCCC VIKWXRMCVRWJES-UHFFFAOYSA-N 0.000 description 1
- QRFOYUWHJWKKDJ-UHFFFAOYSA-N CC=1NC2=CC=C(C=C2C=1C(=O)OC1CCN(CC1)CCCC)F Chemical compound CC=1NC2=CC=C(C=C2C=1C(=O)OC1CCN(CC1)CCCC)F QRFOYUWHJWKKDJ-UHFFFAOYSA-N 0.000 description 1
- DROFYUXUDQKEFA-UHFFFAOYSA-N CCCCN(CC1)CCC1OC(C(C(C=CC=C1)=C1N1CCC2C)=C1S2=O)=O Chemical compound CCCCN(CC1)CCC1OC(C(C(C=CC=C1)=C1N1CCC2C)=C1S2=O)=O DROFYUXUDQKEFA-UHFFFAOYSA-N 0.000 description 1
- JCSFDGNZGZGTIE-UHFFFAOYSA-N CCCCN1CCC(CC1)NC(=O)C2=C3N(CCCN3C4=CC=CC=C42)C Chemical compound CCCCN1CCC(CC1)NC(=O)C2=C3N(CCCN3C4=CC=CC=C42)C JCSFDGNZGZGTIE-UHFFFAOYSA-N 0.000 description 1
- UYUSJBPGGPGRRT-UHFFFAOYSA-N CCCCN1CCC(CC1)NC(=O)C2=C3N=C(C=CN3C4=CC=CC=C42)C Chemical compound CCCCN1CCC(CC1)NC(=O)C2=C3N=C(C=CN3C4=CC=CC=C42)C UYUSJBPGGPGRRT-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
- 229920005439 Perspex® Polymers 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 229940008309 acetone / ethanol Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- UNSCWVXFEJEHEZ-UHFFFAOYSA-N benzyl pyrimido[1,2-a]indole-10-carboxylate Chemical compound C12=CC=CC=C2N2C=CC=NC2=C1C(=O)OCC1=CC=CC=C1 UNSCWVXFEJEHEZ-UHFFFAOYSA-N 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 210000004921 distal colon Anatomy 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000005216 enteric neuron Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- CJHXMQCYEILGFT-UHFFFAOYSA-N ethyl 2-(2-nitrophenyl)acetate Chemical compound CCOC(=O)CC1=CC=CC=C1[N+]([O-])=O CJHXMQCYEILGFT-UHFFFAOYSA-N 0.000 description 1
- LANJRSBZGRDIPG-UHFFFAOYSA-N ethyl 6,7,8,9-tetrahydropyrido[1,2-a]indole-10-carboxylate Chemical compound C12=CC=CC=C2C(C(=O)OCC)=C2N1CCCC2 LANJRSBZGRDIPG-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLSMFKSTNGKWQX-UHFFFAOYSA-N hydroxyacetone Chemical compound CC(=O)CO XLSMFKSTNGKWQX-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- HSLDUAFBCXHBHM-UHFFFAOYSA-N methyl 1-methyl-3,4-dihydro-2h-pyrimido[1,2-a]indole-10-carboxylate Chemical compound C12=CC=CC=C2C(C(=O)OC)=C2N1CCCN2C HSLDUAFBCXHBHM-UHFFFAOYSA-N 0.000 description 1
- CVLQVYGGVIIUDI-UHFFFAOYSA-N methyl 2,4-dimethylpyrimido[1,2-a]indole-10-carboxylate Chemical compound CC1=CC(C)=NC2=C(C(=O)OC)C3=CC=CC=C3N21 CVLQVYGGVIIUDI-UHFFFAOYSA-N 0.000 description 1
- FPAAYSLTBWGWJE-UHFFFAOYSA-N methyl 6,7-dihydropyrido[1,2-a]indole-10-carboxylate Chemical compound C12=CC=CC=C2C(C(=O)OC)=C2N1CCC=C2 FPAAYSLTBWGWJE-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 108091048468 miR-383 stem-loop Proteins 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- BTVLHRJXWYIQLD-UHFFFAOYSA-N n-(2-piperidin-1-ylethyl)-1h-indole-3-carboxamide Chemical compound C=1NC2=CC=CC=C2C=1C(=O)NCCN1CCCCC1 BTVLHRJXWYIQLD-UHFFFAOYSA-N 0.000 description 1
- XCEAESKIYSJHOH-UHFFFAOYSA-N n-(piperidin-4-ylmethyl)-3,4-dihydro-2h-[1,3]oxazino[3,2-a]indole-10-carboxamide Chemical compound C=12OCCCN2C2=CC=CC=C2C=1C(=O)NCC1CCNCC1 XCEAESKIYSJHOH-UHFFFAOYSA-N 0.000 description 1
- QBQNECQABSHBMX-UHFFFAOYSA-N n-[(1-benzylpiperidin-4-yl)methyl]-1h-indole-3-carboxamide Chemical compound C=1NC2=CC=CC=C2C=1C(=O)NCC(CC1)CCN1CC1=CC=CC=C1 QBQNECQABSHBMX-UHFFFAOYSA-N 0.000 description 1
- NIYNWNTYCWPIAV-UHFFFAOYSA-N n-[(1-benzylpiperidin-4-yl)methyl]-3,4-dihydro-2h-[1,3]oxazino[3,2-a]indole-10-carboxamide;oxalic acid Chemical compound OC(=O)C(O)=O.C=12OCCCN2C2=CC=CC=C2C=1C(=O)NCC(CC1)CCN1CC1=CC=CC=C1 NIYNWNTYCWPIAV-UHFFFAOYSA-N 0.000 description 1
- PEARSKNDBBJILD-UHFFFAOYSA-N n-[(1-butylpiperidin-4-yl)methyl]-2-(4-chlorobutoxy)-1h-indole-3-carboxamide Chemical compound C1CN(CCCC)CCC1CNC(=O)C1=C(OCCCCCl)NC2=CC=CC=C12 PEARSKNDBBJILD-UHFFFAOYSA-N 0.000 description 1
- CJUSKZSGCCISCW-UHFFFAOYSA-N n-[(1-butylpiperidin-4-yl)methyl]-8-fluoro-3,4-dihydro-2h-[1,3]oxazino[3,2-a]indole-10-carboxamide Chemical compound C1CN(CCCC)CCC1CNC(=O)C(C1=CC(F)=CC=C11)=C2N1CCCO2 CJUSKZSGCCISCW-UHFFFAOYSA-N 0.000 description 1
- QJFNLLQVMIGYEG-UHFFFAOYSA-N n-[(1-butylpiperidin-4-yl)methyl]-[1,3]thiazolo[3,2-a]indole-4-carboxamide Chemical compound C1CN(CCCC)CCC1CNC(=O)C1=C2SC=CN2C2=CC=CC=C21 QJFNLLQVMIGYEG-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 229960001779 pargyline Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002325 prokinetic agent Substances 0.000 description 1
- 229960005335 propanol Drugs 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- VUVGMQNYJPPCCC-UHFFFAOYSA-N pyrido[1,2-a]indole Chemical class C1=CC=CC2=CC3=CC=CC=C3N21 VUVGMQNYJPPCCC-UHFFFAOYSA-N 0.000 description 1
- HBBKFNCURJQICW-UHFFFAOYSA-N pyrimido[1,2-a]indole Chemical class C1=CC=NC2=CC3=CC=CC=C3N21 HBBKFNCURJQICW-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical group 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929205428A GB9205428D0 (en) | 1992-03-12 | 1992-03-12 | Pharmaceuticals |
| GB9205428 | 1992-03-12 | ||
| GB9218846 | 1992-09-05 | ||
| GB929218846A GB9218846D0 (en) | 1992-09-05 | 1992-09-05 | Pharmaceuticals |
| GB9227045 | 1992-12-29 | ||
| GB929227045A GB9227045D0 (en) | 1992-12-29 | 1992-12-29 | Pharmaceuticals |
| GB9300506 | 1993-03-10 | ||
| PCT/GB1993/000506 WO1993018036A1 (en) | 1992-03-12 | 1993-03-10 | Condensed indole derivatives as 5ht4-receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI944204A0 FI944204A0 (fi) | 1994-09-12 |
| FI944204L FI944204L (fi) | 1994-09-12 |
| FI107158B true FI107158B (fi) | 2001-06-15 |
Family
ID=27266092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI944204A FI107158B (fi) | 1992-03-12 | 1994-09-12 | Menetelmä kondensoitujen indolikarboksylaatti- ja indolikarboksiamidijohdannaisten valmistamiseksi |
Country Status (29)
| Country | Link |
|---|---|
| EP (2) | EP0884319B1 (cs) |
| JP (1) | JP2831467B2 (cs) |
| KR (1) | KR100282730B1 (cs) |
| CN (2) | CN1043893C (cs) |
| AP (1) | AP401A (cs) |
| AT (2) | ATE266033T1 (cs) |
| AU (1) | AU671102B2 (cs) |
| CA (1) | CA2131797C (cs) |
| CY (1) | CY2510B1 (cs) |
| CZ (1) | CZ286194B6 (cs) |
| DE (2) | DE69333504T2 (cs) |
| DK (2) | DK0630376T3 (cs) |
| ES (2) | ES2132223T3 (cs) |
| FI (1) | FI107158B (cs) |
| GR (1) | GR3030668T3 (cs) |
| HU (1) | HU219121B (cs) |
| IL (1) | IL105003A (cs) |
| MA (1) | MA22819A1 (cs) |
| MX (1) | MX9301348A (cs) |
| MY (1) | MY110110A (cs) |
| NO (1) | NO303638B1 (cs) |
| NZ (1) | NZ249565A (cs) |
| PT (1) | PT884319E (cs) |
| RU (1) | RU2104279C1 (cs) |
| SG (1) | SG50693A1 (cs) |
| SI (1) | SI9300114B (cs) |
| SK (1) | SK281423B6 (cs) |
| UA (1) | UA41311C2 (cs) |
| WO (1) | WO1993018036A1 (cs) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5852014A (en) * | 1992-03-12 | 1998-12-22 | Smithkline Beecham P.L.C. | Condensed indole derivatives as 5HT4 -receptor antagonists |
| US5998409A (en) * | 1992-03-12 | 1999-12-07 | Smithkline Beecham Plc | Condensed indole derivatives as 5HT4 -receptor antagonists |
| GB9316195D0 (en) * | 1993-08-05 | 1993-09-22 | Smithkline Beecham Plc | Pharmaceuticals |
| MX9305947A (es) * | 1992-09-29 | 1994-06-30 | Smithkline Beecham Plc | Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen. |
| EP0664794A1 (en) * | 1992-10-16 | 1995-08-02 | Smithkline Beecham Plc | N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-ht4 receptor antagonists |
| NZ257545A (en) * | 1992-11-05 | 1997-01-29 | Smithkline Beecham Plc | Heterocyclic (especially piperidine) derivatives and pharmaceutical compositions |
| FR2699921B1 (fr) * | 1992-12-30 | 1995-02-10 | Synthelabo | Dérivés d'acide 2-(thien-2-yl)imidazo[2,1-b]benzothiazole-3-acétique, leur préparation et leur application en thérapeutique. |
| GB9303340D0 (en) * | 1993-02-19 | 1993-04-07 | Smithkline Beecham Plc | Pharmaceuticals |
| GB9310582D0 (en) * | 1993-05-22 | 1993-07-07 | Smithkline Beecham Plc | Pharmaceuticals |
| GB9312348D0 (en) * | 1993-06-16 | 1993-07-28 | Smithkline Beecham Plc | Pharmaceuticals |
| KR100219922B1 (ko) * | 1996-05-16 | 1999-09-01 | 이서봉 | 신규한 항바이러스성 6-아릴옥시 및 6-아릴카르보닐 2,4-피리미딘디온 유도체 및 그의 제조 방법 |
| US6013666A (en) * | 1996-07-02 | 2000-01-11 | Sang Sup Jew | Oxirane carboxylic acid derivative and its manufacturing method |
| ATE197588T1 (de) * | 1996-08-16 | 2000-12-15 | Smithkline Beecham Plc | Verfahren zur herstellung von n- (1-n-butyl-4- piperidinyl)methyl) -3,4-dihydro -2h-(1, 3)oxazino(3,2-a)indol-10-carboxamid und salze sowie zwischenprodukte in dem verfahren |
| US6100397A (en) * | 1996-08-16 | 2000-08-08 | Smithkline Beecham Plc | Process for the preparation of N-[(1-n butyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a] indole-10-carboxamide and salts and intermediates in the process |
| GB9618967D0 (en) * | 1996-09-11 | 1996-10-23 | Smithkline Beecham Plc | Pharmaceuticals |
| GB9725933D0 (en) * | 1997-12-05 | 1998-02-04 | Smithkline Beecham Plc | Pharmaceuticals |
| US6277870B1 (en) * | 1998-05-04 | 2001-08-21 | Astra Ab | Use |
| US6251893B1 (en) * | 1998-06-15 | 2001-06-26 | Nps Allelix Corp. | Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity |
| US20020091271A1 (en) | 1998-07-16 | 2002-07-11 | Smithkline Beecham Plc | Process for the preparation of an indole derivative |
| GB9819035D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Res Ltd | Chemical compounds VII |
| AU758807B2 (en) * | 1998-09-10 | 2003-03-27 | F. Hoffmann-La Roche Ag | Dihydrobenzodioxine carboxamide and ketone derivatives as 5-HT4 receptor antagonists |
| GB9820294D0 (en) * | 1998-09-17 | 1998-11-11 | Smithkline Beecham Plc | Pharmaceuticals |
| US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| US7230000B1 (en) | 1999-10-27 | 2007-06-12 | Cytokinetics, Incorporated | Methods and compositions utilizing quinazolinones |
| AU2005203196B9 (en) * | 2000-08-07 | 2009-04-09 | Glaxo Group Limited | The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions |
| AU782863C (en) * | 2000-08-07 | 2006-08-31 | Glaxo Group Limited | The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions |
| MXPA03001210A (es) * | 2000-08-07 | 2004-08-12 | Smithkline Beecham Corp | Uso de antagonista del receptor 5-ht4 en la fabricacion de un medicamento para la profilaxis o tratamiento de fibrilacion atrial. |
| AU782870C (en) * | 2000-08-07 | 2007-03-15 | Glaxo Group Limited | The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions |
| NZ535261A (en) * | 2000-08-08 | 2004-12-24 | Smithkline Beecham P | A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide |
| WO2002011733A1 (en) * | 2000-08-08 | 2002-02-14 | Smithkline Beecham P.L.C. | Pharmaceutical composition comprising condensed indole compound |
| KR100967782B1 (ko) * | 2002-02-14 | 2010-07-05 | 글락소 그룹 리미티드 | Ｎ-((1-Ｎ-부틸-4-피페리디닐)메틸)-3,4-디하이드로-2Ｈ-(1,3)옥사지노(3,2-ａ)인돌-10-카복스아미드 또는 그의 염을포함하는 제약 조성물, 및 건식 과립화를 포함하는 그의제조 방법 |
| JP2005529076A (ja) | 2002-02-15 | 2005-09-29 | サイトキネティクス・インコーポレーテッド | キナゾリノンの合成 |
| CA2485148A1 (en) | 2002-05-09 | 2003-11-20 | Cytokinetics, Inc. | Pyrimidinone compounds, compositions and methods |
| JP2005530785A (ja) | 2002-05-09 | 2005-10-13 | サイトキネティクス・インコーポレーテッド | 化合物、組成物、及び方法 |
| GB0211230D0 (en) | 2002-05-16 | 2002-06-26 | Medinnova Sf | Treatment of heart failure |
| US7038048B2 (en) | 2002-05-23 | 2006-05-02 | Cytokinetics, Inc. | 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use |
| JP2005538062A (ja) | 2002-06-14 | 2005-12-15 | サイトキネティクス・インコーポレーテッド | 化合物、組成物、および方法 |
| EP1537089A4 (en) | 2002-07-23 | 2008-04-16 | Cytokinetics Inc | CONNECTIONS, COMPOSITIONS AND PROCEDURES |
| US7557115B2 (en) | 2002-09-30 | 2009-07-07 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| ITMI20031467A1 (it) * | 2003-07-18 | 2005-01-19 | Acraf | Farmaco attivo nel dolore neuropatico |
| ITMI20031468A1 (it) | 2003-07-18 | 2005-01-19 | Acraf | Farmaco ativo nel dolore neuropatico |
| WO2005061460A1 (en) | 2003-12-08 | 2005-07-07 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| AU2004303722B2 (en) | 2003-12-23 | 2010-02-18 | Serodus As | Modulators of peripheral 5-HT receptors |
| JP4612301B2 (ja) * | 2003-12-26 | 2011-01-12 | 広栄化学工業株式会社 | １−アルキル−４−アミノメチルピペリジンの製造法 |
| AU2005313325C1 (en) * | 2004-12-07 | 2011-11-10 | Janssen Pharmaceutica N.V. | Substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives |
| RU2320662C1 (ru) * | 2006-08-24 | 2008-03-27 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ ПИРРОЛО[4,3-b]ИНДОЛЫ, КОМБИНАТОРНАЯ И ФОКУСИРОВАННАЯ БИБЛИОТЕКИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| CN101801937A (zh) | 2007-06-22 | 2010-08-11 | 艾科尔公司 | 喹唑啉酮化合物及其使用方法 |
| GB0905641D0 (en) * | 2009-04-01 | 2009-05-13 | Serodus As | Compounds |
| WO2021116487A1 (en) | 2019-12-13 | 2021-06-17 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of niemann-pick c disease |
| WO2025077825A1 (en) * | 2023-10-13 | 2025-04-17 | Fauna Bio Incorporated | Methods and compositions for treating cardio-pulmonary disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2557342A1 (de) * | 1975-12-19 | 1977-06-30 | Hoechst Ag | Basisch substituierte indolderivate und verfahren zu ihrer herstellung |
| AU622330B2 (en) * | 1989-06-23 | 1992-04-02 | Takeda Chemical Industries Ltd. | Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides |
| CA2030051C (en) * | 1989-11-17 | 2001-08-07 | Haruhiko Kikuchi | Indole derivatives |
| US5189041A (en) * | 1990-11-16 | 1993-02-23 | Syntex (U.S.A.) Inc. | Tricyclic 5-ht3 receptor antagonists |
| GB9103862D0 (en) * | 1991-02-25 | 1991-04-10 | Glaxo Group Ltd | Chemical compounds |
| US5206382A (en) * | 1991-06-27 | 1993-04-27 | Fidia Georgetown Institute For The Neurosciences | Indole derivatives, pharmaceutical compositions and methods of treating neurological and psychiatric disorders |
-
1993
- 1993-03-10 DK DK93905561T patent/DK0630376T3/da active
- 1993-03-10 KR KR1019940703167A patent/KR100282730B1/ko not_active Expired - Fee Related
- 1993-03-10 DE DE69333504T patent/DE69333504T2/de not_active Expired - Lifetime
- 1993-03-10 CA CA2131797A patent/CA2131797C/en not_active Expired - Fee Related
- 1993-03-10 AT AT98114130T patent/ATE266033T1/de active
- 1993-03-10 AU AU36448/93A patent/AU671102B2/en not_active Expired
- 1993-03-10 DE DE69325167T patent/DE69325167T2/de not_active Expired - Lifetime
- 1993-03-10 HU HU9402601A patent/HU219121B/hu unknown
- 1993-03-10 UA UA94095780A patent/UA41311C2/uk unknown
- 1993-03-10 RU RU94040864A patent/RU2104279C1/ru not_active IP Right Cessation
- 1993-03-10 WO PCT/GB1993/000506 patent/WO1993018036A1/en active IP Right Grant
- 1993-03-10 DK DK98114130T patent/DK0884319T3/da active
- 1993-03-10 SK SK1078-94A patent/SK281423B6/sk not_active IP Right Cessation
- 1993-03-10 PT PT98114130T patent/PT884319E/pt unknown
- 1993-03-10 JP JP5515490A patent/JP2831467B2/ja not_active Expired - Lifetime
- 1993-03-10 IL IL10500393A patent/IL105003A/en not_active IP Right Cessation
- 1993-03-10 AP APAP/P/1993/000494A patent/AP401A/en active
- 1993-03-10 ES ES93905561T patent/ES2132223T3/es not_active Expired - Lifetime
- 1993-03-10 MA MA23113A patent/MA22819A1/fr unknown
- 1993-03-10 ES ES98114130T patent/ES2219813T3/es not_active Expired - Lifetime
- 1993-03-10 SI SI9300114A patent/SI9300114B/sl active Search and Examination
- 1993-03-10 CZ CZ19942210A patent/CZ286194B6/cs not_active IP Right Cessation
- 1993-03-10 AT AT93905561T patent/ATE180785T1/de active
- 1993-03-10 MY MYPI93000436A patent/MY110110A/en unknown
- 1993-03-10 EP EP98114130A patent/EP0884319B1/en not_active Expired - Lifetime
- 1993-03-10 SG SG1996008846A patent/SG50693A1/en unknown
- 1993-03-10 EP EP93905561A patent/EP0630376B1/en not_active Expired - Lifetime
- 1993-03-10 NZ NZ249565A patent/NZ249565A/en not_active IP Right Cessation
- 1993-03-11 MX MX9301348A patent/MX9301348A/es not_active IP Right Cessation
- 1993-03-11 CN CN93102648A patent/CN1043893C/zh not_active Expired - Fee Related
- 1993-05-22 CN CN93107234A patent/CN1085083A/zh active Pending
-
1994
- 1994-09-09 NO NO943348A patent/NO303638B1/no not_active IP Right Cessation
- 1994-09-12 FI FI944204A patent/FI107158B/fi not_active IP Right Cessation
-
1999
- 1999-06-30 GR GR990401755T patent/GR3030668T3/el unknown
-
2005
- 2005-04-12 CY CY0500021A patent/CY2510B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI107158B (fi) | Menetelmä kondensoitujen indolikarboksylaatti- ja indolikarboksiamidijohdannaisten valmistamiseksi | |
| BRPI1101193A2 (pt) | Lâmina vibratória, vibrador, oscilador, e dispositivo eletrônico | |
| PT100785A (pt) | Utilizacao de compostos, por exemplo indole-3-carboxilatos, para a producao de medicamentos, compostos ai utilizados e composicoes farmaceuticas que os contem. | |
| GB2169292A (en) | Carbocyclic and heterocyclic carbonylmethylene- and carbonylmethylpiperidines and - pyrrolidines as serotonin antagonists | |
| NZ244282A (en) | Benzoxazine and benzodioxane derivatives, analogues and medicaments thereof | |
| US5852014A (en) | Condensed indole derivatives as 5HT4 -receptor antagonists | |
| US5998409A (en) | Condensed indole derivatives as 5HT4 -receptor antagonists | |
| JP2006519798A (ja) | ５ＨＴ２ｃ受容体に活性を有する化合物及びその使用 | |
| KR20010102006A (ko) | Ａβ 원섬유 형성 억제제로서의 피페리딘 및 피페라진유도체 | |
| EP0712406B1 (en) | Condensed indole derivatives as 5-ht 4-receptor antagonists | |
| KR20000029564A (ko) | 5ＨＴ2ｃ길항제및Ｄ2길항제를함유하는약제학적조성물 | |
| HK1012352B (en) | Condensed indole derivatives as 5-ht4-receptor antagonists | |
| WO2025016379A1 (zh) | 氮杂环丁烷类化合物及其医药用途 | |
| PL172692B1 (pl) | Skondensowane pochodne indolu PL | |
| WO2014016766A1 (en) | Guanidine derivatives as trpc modulators | |
| SA93130459B1 (ar) | مضادات مستفبلات 5-ht4 غير متجانسة الحلقة | |
| ITMI961861A1 (it) | Derivati tetraciclici spiro-condensati | |
| HK1012347B (en) | Condensed indole derivatives as 5-ht 4-receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MA | Patent expired |